BRIEF—Chugai files to broaden Japanese Tecentriq label

Chugai Pharmaceutical has filed to broaden the Japanese label for the anti-PD-L1 monoclonal antibody Tecentriq (atezolizumab) for the first line treatment of extensive-stage small cell lung cancer (ES-SCLC).

The filing comes days after Swiss pharma giant Roche filed for the same indication in the USA, under the Priority Review scheme.

Chugai’s Yasushi Ito said: “Tecentriq is the first cancer immunotherapy treatment to extend overall survival and progression-free survival in the first line treatment of ES-SCLC, and has recently been designated as an orphan drug by MHLW.”